Severe hepatic cytolysis: incidence and risk factors in... : AIDS (original) (raw)

Fact Track

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998

Savès, Mariannea; Vandentorren, Stéphaniea; Daucourt, Valentina; Marimoutou, Catherinea,b; Dupon, Michelb,c; Couzigou, Patriceb,d; Bernard, Noëlleb,e; Mercié, Patrickb,f; Dabis, Françoisa,b the Groupe d‚Epidémiologie Clinique du Sida en Aquitaine (GECSA)

From the aINSERM U.330, Université Victor Segalen Bordeaux 2, Bordeaux, bCentre d‚Information et de Soins de l‚Immunodéficience Humaine (CISIH), Centre Hospitalier Universitaire (CHU) de Bordeaux, cService de Médecine Interne et Maladies Infectieuses, Hôpital Pellegrin, CHU de Bordeaux, dService d‚Hépatologie, Hôpital Haut-Lévèque, CHU de Bordeaux, eService de Medecine Interne, Hôpital Saint-André, CHU de Bordeaux, fService de Medecine Interne, Hôpital Haut-Lévèque, CHU de Bordeaux, Bordeaux, France. *see Appendix.

Sponsorship: The Aquitaine Cohort is supported by a grant of the Agence Nationale de Recherches sur le SIDA (ANRS, France), within the Coordinated Action no. 7 (Cohorts).

Note: This paper was reported in part at the 39th Interdisciplinary Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, USA, September 26-29, 1999.

Correspondence to Professor François Dabis, INSERM U 330, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat 33076 Bordeaux Cedex, France. Fax: 33-5-57-57-11-72; e-mail: [email protected]

Received: 15 July 1999; accepted: 23 September 1999.

Abstract

Objective:

To study hepatic cytolysis in patients treated by highly active antiretroviral therapy (HAART) with protease inhibitor or with two nucleoside reverse transcriptase inhibitors (NRTIs).

Methods:

We selected patients of the Aquitaine Cohort who initiated HAART or two NRTIs before 1 January 1998, had alanine amino-transferase (ALT) ≤ 200 IU/l at baseline and at least one follow-up measure. Cox model was used to study the association between occurrence of severe hepatic cytolysis (ALT>200 IU/l) and age, gender, HIV transmission group, baseline CD4 and CD8 cell count, history of hepatic cytolysis, antiretroviral drug, baseline liver enzymes (WHO classification level 0: ≤?50 IU/l, level 1: 51 to 100, level 2: 101 to 200), hepatitis B and C co-infection.

Results:

Sixty-four of 748 (8.5%) patients treated with HAART and 71 of 1249 (5.7%) treated with two NRTIs developed cytolysis. The probability of occurrence was 7.9% after 1 year [95% confidence interval (CI), 5.9-10.4] for patients treated with HAART and 4.8% (95% CI, 3.6-6.4) for patients treated with two NRTIs (log-rank test, P = 0.01). The median time to occurrence was 164 days for HAART-treated patients and 252 days for those treated with two NRTIs. In multivariate analysis, the history of cytolysis [hazard ratio (HR) = 2.3; 95% CI, 1.2-4.4], baseline value of ALT (HR = 2.4; 95% CI, 1.2-4.8 and HR = 3.3; 95% CI, 1.4-7.4 for levels 1 and 2, respectively), hepatitis B (HR = 3.0; 95% CI, 1.4-6.2) and C co-infections (HR = 3.2; 95% CI, 1.7-6.2) remained significantly associated with the occurrence of severe hepatic cytolysis among HAART-treated patients. History of cytolysis, hepatitis B and C were associated with cytolysis in patients treated with two NRTIs (HR = 14.8, 2.6 and 2.7, respectively).

Conclusion:

Hepatic cytolysis is more frequent among patients treated with HAART than with two NRTIs. Hepatitis B and C are the major risk factors after initiation of HAART or treatment with NRTIs. Co-infections with hepatitis B virus or hepatitis C virus may modify the management of HIV-infected patients treated by HAART.